PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

  • ID: 3735090
  • Report
  • Region: Global
  • 440 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Dainippon Sumitomo
  • Eli Lilly
  • Janssen
  • Lundbeck
  • MORE
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

Summary

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Highlights

Key Questions Answered

- The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
- The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder?
- The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

- The main driver of growth in the bipolar disorder market will be the uptake of novel atypical antipsychotic products, such as Otsuka/Lundbeck’s Abilify Maintena and Allergan/Gedeon Richter/Mitsubishi Tanabe’s Vraylar. These agents are forecast to be the highest selling bipolar disorder products by 2024, accounting for 34.9% of the bipolar disorder market in the 8MM.
- There are very few products approved for the treatment of major depressive episodes, despite the fact that patients most commonly experience this episode type. This unmet need is not expected to be addressed during the forecast period due to the sparsity of the late-stage pipeline.
- The biggest barrier for growth in the bipolar disorder market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
- Considerable opportunity remains for products with superior safety profiles compared to the currently available drugs. KOLs noted that EPS and metabolic changes were significant concerns related to the antipsychotic drugs.

Scope

- Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized bipolar disorder market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the bipolar disorder therapeutics market.
- Pipeline analysis: focus on two late-stage pipeline bipolar disorder drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of off-label treatments.
- Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global bipolar disorder therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Dainippon Sumitomo
  • Eli Lilly
  • Janssen
  • Lundbeck
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.3 Symptoms

3.4 Prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Sources Not Used

4.4.3 Forecast Assumptions and Methods

4.5 Epidemiological Forecast of Bipolar Disorder (2014-2024)

4.5.1 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder

4.5.2 12-Month Total Prevalent Cases of Bipolar I

4.5.3 12-Month Total Prevalent Cases of Bipolar II

4.5.4 12-Month Total Prevalent Cases of Cyclothymic Disorder

4.5.5 Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder

4.5.6 Age-Specific 12-Month Total Prevalent Cases of Bipolar I

4.5.7 Age-Specific 12-Month Total Prevalent Cases of Bipolar II

4.5.8 Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder

4.5.9 Sex-Specific 12-Month Total Prevalent Cases of Bipolar I

4.5.10 Sex-Specific 12-Month Total Prevalent Cases of Bipolar II

4.5.11 Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder

4.5.12 Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis Overview

5.1.1 Clinical Evaluation

5.1.2 Screening Tools

5.2 Treatment Overview

5.2.1 Treatment Initiation and Maintenance Therapy

5.2.2 Manic or Mixed Episodes

5.2.3 Acute Agitation

5.2.4 Hypomanic Episodes

5.2.5 Major Depressive Episodes

5.2.6 Rapid Cycling

5.2.7 Cyclothymia

5.2.8 Other Treatment Factors

5.3 Treatment Guidelines and Leading Prescribed Drugs

5.4 US

5.5 5EU

5.6 Japan

5.7 Canada

6 Competitive Assessment

6.1 Overview

6.2 Product Profiles - Major Brands

6.2.1 Lithium

6.2.2 Anticonvulsants

6.2.3 Typical Antipsychotics

6.2.4 Atypical Antipsychotics

6.2.5 Antidepressants

6.3 Other Therapeutic Classes

7 Unmet Need and Opportunity

7.1 Overview

7.2 Effective Treatment Options for Bipolar Depression

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Mood Stabilizers with Improved Safety Profiles

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Education for Physicians in Order to Improve Diagnosis Rates

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Novel Drugs Developed Specifically for Bipolar Disorder

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.1.1 Clinical Trials by Class of Therapy

8.2 Promising Drugs in Clinical Development

8.2.1 Abilify Maintena

8.2.2 ITI-007

8.3 Off-label Pipeline and Recently Approved Therapies

8.4 Promising Drugs in Early-Stage Development

8.5 Other Drugs in Development

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Otsuka

9.3.2 AstraZeneca

9.3.3 Eli Lilly

9.3.4 Allergan

9.3.5 Dainippon Sumitomo

9.3.6 Janssen

9.3.7 Lundbeck

9.3.8 Meiji Seika

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers - Global Issues

10.2 United States

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 Canada

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Diagnosed Bipolar Disorder Patients

11.4.2 Percent Drug-Treated Patients

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Individual Drug Assumptions

11.4.6 Generic Erosion

11.5 Primary Research - KOLs Interviewed for this Report

11.6 Primary Research - Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Epidemiologist

11.7.4 Global Director of Therapy Research and Analysis

11.8 About us

11.9 Disclaimer

1.1 List of Tables

Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM

Table 2: DSM-V Bipolar Disorder Specifiers

Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder

Table 4: Risk Factors and Comorbidities for Bipolar Disorder

Table 5: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder I

Table 6: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder I

Table 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder II

Table 8: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder II

Table 9: 8MM, Sources Used to Forecast 12-Month Total Prevalent Cases of Cyclothymic Disorder

Table 10: 8MM, Sources Used to Forecast Lifetime Total Prevalent Cases of Cyclothymic Disorder

Table 11: 8MM, 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages =13 Years, N (Row %), 2014

Table 12: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages =13 Years, 2014-2024

Table 13: 8MM, 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages =13 Years, 2014-2024

Table 14: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages =13 Years, 2014-2024

Table 15: 8MM, Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages =13 Years, N (Row %), 2014

Table 16: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages =13 Years, N (Row %), 2014

Table 17: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages =13 Years, N (Row %), 2014

Table 18: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages =13 Years, N (Row %), 2014

Table 19: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages =13 Years, N (Row %), 2014

Table 20: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages =13 Years, N (Row %), 2014

Table 21: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages =13 Years, N (Row %), 2014

Table 22: Screening Tools Used for Bipolar Disorder

Table 23: Treatment Guidelines for Bipolar Disorder

Table 24: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014

Table 25: Country Profile - US

Table 26: Country Profile - 5EU

Table 27: Country Profile - Japan

Table 28: Country Profile - Canada

Table 29: Leading Treatments for Bipolar Disorder, 2015

Table 30: Product Profile - Lithium

Table 31: Lithium SWOT Analysis, 2015

Table 32: Global Sales Forecasts ($m) for Lithium, 2014-2024

Table 33: Product Profile - Carbamazepine

Table 34: Efficacy Results for Equetro in Bipolar Mania Trials

Table 35: Adverse Events at =5% Incidence in Bipolar Mania Trials of Equetro

Table 36: Carbamazepine SWOT Analysis, 2015

Table 37: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024

Table 38: Product Profile - Lamotrigine

Table 39: Adverse Events at =5% Incidence in Bipolar Maintenance Trials of Lamictal

Table 40: Lamotrigine SWOT Analysis, 2015

Table 41: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024

Table 42: Product Profile - Valproate

Table 43: Efficacy Results for Depakote in Bipolar Mania Trials

Table 44: Adverse Events at =5% Incidence in Bipolar Mania Trials of Depakote

Table 45: Valproate SWOT Analysis, 2015

Table 46: Global Sales Forecasts ($m) for Valproate, 2014-2024

Table 47: Typical Antipsychotics by Chemical Class

Table 48: Typical antipsychotics SWOT Analysis, 2015

Table 49: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024

Table 50: Product Profile - Adasuve

Table 51: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients

Table 52: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve

Table 53: Adasuve SWOT Analysis, 2015

Table 54: Global Sales Forecasts ($m) for Adasuve, 2014-2024

Table 55: Product Profile - Abilify

Table 56: Efficacy Results for Abilify in Bipolar Mania Trials

Table 57: Efficacy Results for Abilify in Agitation Trials

Table 58: Adverse Events at =2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify

Table 59: Abilify SWOT Analysis, 2015

Table 60: Global Sales Forecasts ($m) for Abilify, 2014-2024

Table 61: Product Profile - Geodon

Table 62: Adverse Events at =2% Incidence in Bipolar Mania Trials of Geodon

Table 63: Geodon SWOT Analysis, 2015

Table 64: Global Sales Forecasts ($m) for Geodon, 2014-2024

Table 65: Product Profile - Latuda

Table 66: Efficacy Results for Latuda in Bipolar Depression Trials

Table 67: Adverse Events at =2% Incidence in Bipolar Depression Trials of Latuda

Table 68: Latuda SWOT Analysis, 2015

Table 69: Global Sales Forecasts ($m) for Latuda, 2014-2024

Table 70: Product Profile - Risperdal

Table 71: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes

Table 72: Adverse Events at =2% Incidence in Bipolar Mania Trials of Risperdal

Table 73: Adverse Events at =2% Incidence in Bipolar Maintenance Trials of Risperdal Consta

Table 74: Risperdal SWOT Analysis, 2015

Table 75: Global Sales Forecasts ($m) for Risperdal, 2014-2024

Table 76: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024

Table 77: Product Profile - Saphris

Table 78: Efficacy Results for Saphris in Bipolar Mania Studies

Table 79: Adverse Events at =2% Incidence in Bipolar I Disorder Trials of Saphris

Table 80: Saphris SWOT Analysis, 2015

Table 81: Global Sales Forecasts ($m) for Saphris, 2014-2024

Table 82: Product Profile - Seroquel

Table 83: Efficacy Results for Seroquel in Bipolar Mania Studies

Table 84: Efficacy Results for Seroquel in Bipolar Depression Trials

Table 85: Efficacy Results for Seroquel XR in Bipolar Disorder Trials

Table 86: Adverse Events at =2% Incidence in Bipolar Disorder Trials of Seroquel

Table 87: Adverse Events at =2% Incidence in Bipolar Disorder Trials of Seroquel XR

Table 88: Seroquel SWOT Analysis, 2015

Table 89: Global Sales Forecasts ($m) for Seroquel, 2014-2024

Table 90: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024

Table 91: Product Profile - Symbyax

Table 92: Efficacy Results for Symbyax in Bipolar Depression Trials

Table 93: Adverse Events at =2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax

Table 94: Symbyax SWOT Analysis, 2015

Table 95: Global Sales Forecasts ($m) for Symbyax, 2014-2024

Table 96: Product Profile - Vraylar

Table 97: Vraylar SWOT Analysis, 2015

Table 98: Global Sales Forecast ($) for Vraylar, 2014-2024

Table 99: Product Profile - Zyprexa

Table 100: Adverse Events at =2% Incidence in Bipolar Mania Trials of Zyprexa

Table 101: Adverse Events at =2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania

Table 102: Zyprexa SWOT Analysis, 2015

Table 103: Global Sales Forecasts ($m) for Zyprexa, 2014-2024

Table 104: Product Information for the Most Commonly Prescribed “Other Antipsychotics”

Table 105: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder

Table 106: Antidepressants SWOT Analysis, 2015

Table 107: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024

Table 108: Summary of Minor Therapeutic Classes, 2015

Table 109: Unmet Need and Opportunity in Bipolar Disorder

Table 110: Product Profile - Abilify Maintena

Table 111: Adverse Events at =2% Incidence in a Schizophrenia Trial of Abilify Maintena

Table 112: Abilify Maintena SWOT Analysis, 2015

Table 113: Global Sales Forecast ($) for Abilify Maintena, 2014-2024

Table 114: Product Profile - ITI-007

Table 115: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial

Table 116: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007

Table 117: ITI-007 SWOT Analysis, 2015

Table 118: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs

Table 119: Drugs in Development, 2015

Table 120: Key Companies in the Bipolar Disorder Market in the 8MM, 2015

Table 121: Otsuka’s Bipolar Disorder Portfolio Assessment, 2015

Table 122: AstraZeneca’s Bipolar Disorder Portfolio Assessment, 2015

Table 123: Eli Lilly’s Bipolar Disorder Portfolio Assessment, 2015

Table 124: Allergan’s Bipolar Disorder Portfolio Assessment, 2015

Table 125: Dainippon Sumitomo’s Bipolar Disorder Portfolio Assessment, 2015

Table 126: Janssen Bipolar Disorder Portfolio Assessment, 2015

Table 127: Lundbeck Bipolar Disorder Portfolio Assessment, 2015

Table 128: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015

Table 129: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024

Table 130: Bipolar Disorder Market - Drivers and Barriers, 2014-2024

Table 131: Sales Forecast ($m) for Bipolar Disorder in the US, 2014-2024

Table 132: Key Events Impacting Sales for Bipolar Disorder in the US, 2014-2024

Table 133: Bipolar Disorder Market in the US - Drivers and Barriers, 2014-2024

Table 134: Sales Forecasts ($m) for Bipolar Disorder in the 5EU, 2014-2024

Table 135: Key Events Impacting Sales for Bipolar Disorder in the 5EU, 2014-2024

Table 136: Bipolar Disorder Market in the 5EU - Drivers and Barriers, 2014-2024

Table 137: Sales Forecasts ($m) for Bipolar Disorder in Japan, 2014-2024

Table 138: Key Events Impacting Sales for Bipolar Disorder in Japan, 2014-2024

Table 139: Bipolar Disorder Market in Japan - Drivers and Barriers, 2014-2024

Table 140: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024

Table 141: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024

Table 142: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024

Table 143: Key Launch Dates

Table 144: Key Patent Expiries

Table 145: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: The Etiology and Pathophysiology of Bipolar Disorders

Figure 2: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages =13 Years, 2014-2024

Figure 3: 8MM, Bipolar II 12-Month Total Prevalent Cases, Both Sexes, Ages =13 Years, 2014-2024

Figure 4: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages =13 Years, 2014-2024

Figure 5: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, 2014

Figure 6: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, 2014

Figure 7: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, 2014

Figure 8: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages =13 Years, 2014

Figure 9: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages =13 Years, 2014

Figure 10: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages =13 Years, 2014

Figure 11: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Men, Ages =13 Years, 2014

Figure 12: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Women, Ages =13 Years, 2014

Figure 13: The Effects of Lithium on Neurotransmission

Figure 14: The Effects of Lithium on Second Messenger Pathways

Figure 15: Bipolar Disorder Therapeutics - Class of Therapy, 2016

Figure 16: Bipolar Disorder - Phase II-III Pipeline, 2015

Figure 17: Clinical and Commercial Positioning of Abilify Maintena

Figure 18: Clinical and Commercial Positioning of ITI-007

Figure 19: Global Sales of Products for Bipolar Disorder by Company, 2014-2024

Figure 20: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024

Figure 21: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 22: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 23: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 24: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 25: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 26: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 27: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 28: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 29: Global Sales for Bipolar Disorder by Region, 2014-2024

Figure 30: Global Sales for Bipolar Disorder by Drug Class, 2014-2024

Figure 31: Sales for Bipolar Disorder in the US by Drug Class, 2014-2024

Figure 32: Sales for Bipolar Disorder in the 5EU by Drug Class, 2014-2024

Figure 33: Sales for Bipolar Disorder in Japan by Drug Class, 2014-2024

Figure 34: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Otsuka
AstraZeneca
Eli Lilly
Allergan
Dainippon Sumitomo
Janssen
Lundbeck
Meiji Seika
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll